Clinical trials: Mycobacterium Avium Intracellulare Complex (MAC)
Mycobacterium Infections, Nontuberculous
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
The primary objective of this study is to generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the…
- Trial name
- ARISE (NCT04677543)
- Testing
- ALIS, Azithromycin, Ethambutol
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 99 people
- Sponsor
- Insmed Incorporated
Mycoses, Mycobacterium Avium-Intracellulare Infection
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
PRIMARY: To determine the efficacy of azithromycin and rifabutin alone and in combination for the prevention of disseminated Mycobacterium avium Complex (MAC) infection in HIV-infected patients.
- Conditions
- Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Trial name
- NCT00002122
- Testing
- Azithromycin, Rifabutin, Fluconazole
- Where
- 12 sites in United States
- Volunteers
- 720 people
- Sponsor
- Pfizer
Nontuberculous Mycobacteria, Mycobacterium Avium Complex
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria
- Trial name
- NCT00600769
- Testing
- Clarithromycin
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- The University of Texas Health Science Center at Tyler
Mycobacterium Avium-intracellulare Infection, HIV Infections
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.
- Trial name
- NCT00002080
- Testing
- Rifabutin
- Where
- United States
- Sponsor
- Pharmacia
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
This study will examine the effectiveness of clofazimine in the prophylaxis of Mycobacterium avium complex infection in HIV infected individuals who are at risk to develop this untreatable opportunistic disease.
- Trial name
- NCT00002058
- Testing
- Clofazimine
- Where
- 2 sites in United States
- Sponsor
- University of California, San Francisco
Mycobacterium Infections, Nontuberculous
Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) 590 mg administered once daily (QD) when added to multi-drug regimen (MDR) in participants with Nontuberculous Mycobacterial (NTM) lung infection…
- Trial name
- CONVERT (NCT02344004)
- Testing
- LAI (Liposomal Amikacin for Inhalation) 590 mg
- Volunteers
- 336 people
- Sponsor
- Insmed Incorporated
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16…
- Trial name
- NCT00000907
- Where
- 24 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-Intracellulare Infection, HIV Infections
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
To evaluate the efficacy and safety of azithromycin given chronically for the treatment of Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available MAC therapy.
- Trial name
- NCT00002089
- Testing
- Azithromycin
- Where
- United States
- Sponsor
- Pfizer
Mycobacterium Avium-intracellulare Infection
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease. II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection.
- Trial name
- NCT00004689
- Testing
- amithiozone, clarithromycin, ethambutol
- Volunteers
- 50 people
- Sponsor
- National Jewish Health
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung…
- Conditions
- Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
- Trial name
- CleaR-MAC (NCT04616924)
- Testing
- RHB-204
- Where
- 25 sites in United States
- Volunteers
- 12 people
- Sponsor
- RedHill Biopharma Limited
Mycobacterium Avium-intracellular Infection, HIV Infections
The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts <= 100 cells/mm3.
- Trial name
- NCT00002336
- Testing
- Clarithromycin
- Where
- 22 sites in United States
- Sponsor
- Abbott
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
The purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and ethambutol (EB) in adult participants with…
- Trial name
- NCT04630145
- Testing
- Bedaquiline, Clarithromycin, Ethambutol
- Where
- 55 sites in Japan, South Korea and 1 more
- Volunteers
- 129 people
- Sponsor
- Janssen Pharmaceutical K.K.
Mycobacterium Avium Intracellulare Complex (MAC)
Mycobacterium Avium Intracellulare Complex (MAC) Study
This study is short course (3 month) multiple drug antibiotic therapy. The purpose of this research study is to evaluate the clinical and radiology response to assess whether drug resistance develops and assess quality of life…
- Trial name
- MAC (NCT00826423)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Mycobacterium Avium Complex Pulmonary Disease
A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study
To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of…
- Trial name
- MAC-PD cohort (NCT05906316)
- Where
- 11 sites in United States, Belgium and 8 more
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
Disseminated infection with Mycobacteria avium complex (MAC) is one of the most common systemic bacterial infections in advanced stages of the acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT00001763
- Testing
- Interleukin-12
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium
Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease
1. To understand the components of PBMC in MAC-LD patients, including T cells, B cells, nature killer cells, and monocyte. 2. To confirm the phenomenon of reduced PBMC response in MAC-LD patients 3.
- Trial name
- NCT02779049
- Testing
- Blood examination
- Where
- Taiwan
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Mycobacterium Avium Complex, Adverse Effects
Improving Tolerance of Treatment of Pulmonary MAC Infections
The purpose of this study is to improve tolerance of treatment of pulmonary Mycobacterium avium Complex disease via the use of therapeutic drug monitoring and the addition of anti-nausea medication or dietary supplements to the…
- Trial name
- ITT-MAC (NCT01719042)
- Testing
- Zofran (8mg), Ensure
- Sponsor
- University of Florida
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
This study is designed to find out whether HIV-positive patients whose immune systems have improved after receiving anti-HIV treatment should take azithromycin to prevent Mycobacterium avium complex (MAC) disease.
- Trial name
- NCT00000947
- Testing
- Azithromycin
- Where
- 19 sites in United States
- Volunteers
- 850 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium Complex
A Study of Standard Drugs for Mycobacterium Avium Complex
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
- Trial name
- NCT04287049
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
This study is designed to evaluate the efficacy and safety of clarithromycin given orally at 1 of 3 doses to treat disseminated Mycobacterium avium complex infections (MAC) in patients with AIDS.
- Trial name
- NCT00000644
- Testing
- Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)